Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29587519 | 1.00 | POLA1 (0.51) | POLA1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL2981802 | 0.90 | POLA1 (0.50) | POLA1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL5749365 | 0.89 | KDM1A (0.58) | POLA1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL31650219 | 0.89 | KDM1A (0.58) | POLA1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL5735496 | 0.83 | KDM1A (0.51) | POLA1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL9252967 | 0.81 | KDM1A (0.50) | POLA1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL5396757 | 0.78 | POLA1 (0.52) | POLA1KDM1ASIGMAR1MEN1KMT2A | |
| SCHEMBL6567499 | 0.78 | KDM1A (0.48) | POLA1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL7967461 | 0.78 | POLA1 (0.52) | POLA1KDM1ASIGMAR1MEN1KMT2A | |
| SCHEMBL6580889 | 0.78 | POLA1 (0.55) | POLA1CYP3A4CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478211-B | Preparation method of etazocine intermediate | 广州一品红制药有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-114478213-B | Method for preparing etazocine intermediate by utilizing micro-channel device | 广州一品红制药有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20210087156-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF BENZODICYCLOALKANE DERIVATIVE, POLYMORPHIC SUBSTANCE THEREOF, AND APPLICATION THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2021-03-25 | — | — | US | disclosed |
| US-10577346-B2 | Benzobicycloalkane derivatives, their preparation and pharmaceutical use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2020-03-03 | — | — | US | disclosed |
| US-20190161468-A1 | BENZODICYCLOALKANE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-05-30 | — | — | US | disclosed |
| US-7384947-B2 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384947-B2 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384947-B2 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2008-06-10 | — | — | US | disclosed |
| US-20060287387-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-12-21 | — | — | US | disclosed |
| US-7144885-B2 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-12-05 | — | — | US | disclosed |
| US-20050165042-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disoroders | BAYER HEALTHCARE LLC | 2005-07-28 | — | — | US | disclosed |
| EP-1478639-A1 | FUSED TRICYCLIC HETEROCYCLES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003072566-A1 | FUSED TRICYCLIC HETEROCYCLES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-09-04 | — | — | WO | disclosed |
| EP-0106487-A2 | Improvements in or relating to novel bridged hexahydrobenz(f)isoquinolines | ELI LILLY AND COMPANY (US) | 1984-04-25 | — | — | EP | disclosed |
| EP-0106486-A2 | Improvements in or relating to novel octahydrobenz(f)isoquinolines | ELI LILLY AND COMPANY (US) | 1984-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287387-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | MKI67, CCNA2, CDK4 | POLA1 419/4885CYP3A4 3416/4885CYP2C9 4183/4885 |
| US-20050165042-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disoroders | MKI67, CCNI, PCNA | POLA1 276/4885CYP3A4 2784/4885CYP2C9 3520/4885 |
| US-20210087156-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF BENZODICYCLOALKANE DERIVATIVE, POLYMORPHIC SUBSTANCE THEREOF, AND APPLICATION THEREOF | CYP3A43, ABCB1, CYP3A5 | POLA1 3826/4885CYP3A4 11/4885CYP2C9 9/4885 |
| US-20190161468-A1 | BENZODICYCLOALKANE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | CYP3A7, CYP2A7, CYP2J2 | POLA1 3157/4885CYP3A4 32/4885CYP2C9 15/4885 |
| US-10577346-B2 | Benzobicycloalkane derivatives, their preparation and pharmaceutical use thereof | CYP3A7, UGT2B7, BDKRB1 | POLA1 3132/4885CYP3A4 35/4885CYP2C9 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.